Associated Papers
Genetic preservation of SLC22A3 in the Admixed and Xhosa populations living in the Western Cape.
Pearce B et al.
Molecular Biology Reports, 2023
Structural basis of organic cation transporter-3 inhibition.
Khanppnavar B et al.
Nature Communications, 2022
36344565 (PubMed )
Supplement: 41467_2022_34284_MOESM1_ESM.pdf
The Impact of Genetic Polymorphisms in Organic Cation Transporters on Renal Drug Disposition.
Zazuli Z et al.
International Journal of Molecular Sciences, 2020
Association between Polymorphisms of OCT1 and Metabolic Response to Metformin in Women with Polycystic Ovary Syndrome.
Chang HH et al.
International Journal of Molecular Sciences, 2019
Genetic Heterogeneity of SLC22 Family of Transporters in Drug Disposition.
Lozano E et al.
Journal of Personalized Medicine, 2018
Effects of the genetic variants of organic cation transporters 1 and 3 on the pharmacokinetics of metformin in Jordanians.
Hakooz N et al.
Drug Metabolism and Personalized Therapy, 2017
Recent advance in the pharmacogenomics of human Solute Carrier Transporters (SLCs) in drug disposition.
Zhou F et al.
Advanced Drug Delivery Reviews, 2017
Influences of organic cation transporter polymorphisms on the population pharmacokinetics of metformin in healthy subjects.
Yoon H et al.
The Aaps Journal, 2013
Role of organic cation transporter 3 (SLC22A3) and its missense variants in the pharmacologic action of metformin.
Chen L et al.
Pharmacogenetics and Genomics, 2010
Functional analysis of human organic cation transporter OCT3 (SLC22A3) polymorphisms.
Sakata T et al.
Journal of Pharmacological Sciences, 2010
Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver.
Nies AT et al.
Hepatology (baltimore, Md.), 2009
Select a paper to view details